Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Total Non-Current Liabilities

Last Annual Value

58.20K

3-Year CAGR

-17%

5-Year CAGR

%

10-Year CAGR

56%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Total Non-Current Liabilities

NTRB · NASDAQ
CompanyTotal Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
58.20K
-10.0%-10.5%N/A 
86.97M
-1.7%70.8%N/A
1.06M
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
1.80M
2.6%-5.1%54.7%
1.54M
-25.8%-58.7%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
11.61M
-13.3%-9.8%-21.7%
901.83K
-5.9%-11.0%N/A
11.80M
-5.7%24.4%63.5%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
76.72M
55.8%27.4%17.3%
IMA logo
ImageneBio Inc
NASDAQ:IMA
8.60M
1.9%-7.7%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
107.00K
-44.9%-28.8%0.7%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15